Award Number: W81XWH-13-1-0461

TITLE: Targeting Tumor Oct4 to Deplete Prostate Tumor- and Metastasis-Initiating Cells

PRINCIPAL INVESTIGATOR: Daotai Nie

CONTRACTING ORGANIZATION: Southern Illinois University School of Medicine, Springfield, IL 62794-9626

REPORT DATE: December 2017

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT:

Approved for public release; distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

	Form Approved				
REPORT DO	OMB No. 0704-0188				
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. <b>PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.</b>					
1. REPORT DATE (DD-MM-YYYY)	2. REPORT TYPE	3. DATES COVERED (From - To)			
December 2017	Final	30Sept2013 - 29Sept2017			
4. TITLE AND SUBTILE		5a. CONTRACT NUMBER			
Targeting Tumor Oct4 to Dep	lete Prostate Tumor- and Metastasis-				
Initiating Cells		5b. GRANT NUMBER			
5		W81XWH-13-1-0461			
		5c. PROGRAM ELEMENT NUMBER			
6. AUTHOR(S) Daotai Nie		5d. PROJECT NUMBER			
		5e. TASK NUMBER			
		5f. WORK UNIT NUMBER			
Email: dnie@siumed.edu					
7. PERFORMING ORGANIZATION NAME(	S) AND ADDRESS(ES)	8. PERFORMING ORGANIZATION REPORT NUMBER			
Couthorn Illinois Universi	try Cohool of				
Souchern minors onivers.					
Medicine, Springfield, IL	62794-9626				
9. SPONSORING / MONITORING AGENCY	( NAME(S) AND ADDRESS(ES)	10. SPONSOR/MONITOR'S ACRONYM(S)			
U.S Army Medical Research a	nd Materiel Command				
Fort Detrick					
Maruland $21702-5012$					
Maryland 21/02-3012		NUMBER(S)			
	MENT				
X Approved for public release; distribution unlimited					
13. SUPPLEMENTARY NOTES					

#### 14. ABSTRACT

Identification of genes driving prostate carcinogenesis will lead to new cancer treatment. The human chromosome 8q24.21 region has been linked with increased risk for prostatic carcinoma but the how this region contributes to prostate carcinogenesis is unknown. We cloned a candidate gene, *POU5F1B* (also called POU5F1P1), in this gene desert of 1.2Mb between *FAM84B* and the *c-MYC* oncogene. *POU5F1B* is a pseudogene of embryonic Oct4 (POU5F1). A recent study found that tumor Oct4 found in prostate cancer cells is due to the gene expression of POU5F1B, not embryonic Oct4 (POU5F1). In a dataset of 171 patients, it was found that tumor Oct4 was significantly increased in primary tumors and markedly increased in metastatic tumors, when compared to normal prostate or adjacent normal tissues. Based on the analyses and our preliminary data, we think, tumor Oct4, expressed from POU5F1B in the prostate cancer susceptibility loci 8q24, is a driver of prostate tumor formation and progression, and therefore, this driver is a novel target of intervention to eliminate prostate cancer. We propose to further determine the roles of tumor Oct4 in prostate tumor formation and metastasis. We hope we can validate whether tumor Oct4 can be targeted to inhibit prostate cancer progression and metastasis. In addition, we will map out the regions critical for Oct4 to promote prostate carcinogenesis so that we can target this region to develop therapeutics for cancer treatment in the future

#### **15. SUBJECT TERMS**

OCT4, cancer stem cells, prostate cancer, metastasis, tumor formation

16. SECURITY CLASS	SIFICATION OF:		17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT	b. ABSTRACT	c. THIS PAGE			<b>19b. TELEPHONE NUMBER</b> (include area code)
U	U	U	UU	37	

# **Table of Contents**

# Page

ntroduction1	1
Body of report	2
Accomplishment and Reportable Outcomes	31
Conclusion and significance	32
Appendices and supporting data	33
References	.33

#### Introduction

Background: Genome-wide association studies (GWAS) have linked human chromosome 8q24.21 region with increased risk for prostatic carcinoma but the how this region contributes to prostate carcinogenesis is unknown. In this gene desert of 1.2Mb between FAM84B and the c-MYC oncogene, POU5F1B (also called POU5F1P1) is a candidate gene with coding capacity. It is a pseudogene of embryonic Oct4 (POU5F1). A recent study found that tumor Oct4 found in prostate cancer cells is due to the gene expression of POU5F1P1 (Hugo name: POU5F1B), not embryonic Oct4 (POU5F1). Our in silico analysis found a significant increase in Oct4 (POU5F1B) in primary tumors and a marked increase in metastatic tumors, when compared to normal prostate or adjacent normal tissues. Tumor Oct4 expression was higher in tumorigenic prostate cancer cells than in non-tumorigenic RWPE-1 cells. Depletion of tumor Oct4 in prostate cancer cells reduced their tumorigenic potential. We cloned tumor Oct4 and found that increased expression of tumor Oct4 in prostate cancer cells stimulated tumor cell motility. Further a significant divergence was found between tumor Oct4 and embryonic Oct4 in regulating Wnt/βcaenin signaling. It is our hypothesis that tumor Oct4, expressed from POU5F1B in the prostate cancer susceptibility loci 8q24, is a driver of prostate tumor formation and progression, and therefore, this driver is a novel target of intervention to eliminate prostate cancer.

**Objective:** The objective is to determine whether tumor Oct4 promotes tumor formation and metastasis, to determine whether tumor Oct4 can be targeted to treat prostate cancer progression, and to elucidate the mechanism involved for tumor Oct4 to promote prostate carcinogenesis.

**Specific Aims:** 1) Investigate whether tumor Oct4 promotes prostate tumor initiation and metastasis.

2) Determine whether tumor Oct4 can be targeted to reduce prostate tumor formation, progression, and metastasis.

3) Elucidate the mechanism involved for tumor Oct4 in promoting prostate carcinogenesis.

#### **BODY OF REPORT**

#### **Scientific portion:**

Task 1. Investigate whether tumor Oct4 promotes prostate tumor initiation and metastasis.

# **1.1 POU5F1B** gene is frequently amplified in prostate cancer especially in metastatic, castration resistant prostate cancer.

With cancer genome data increasingly available, we first determined whether POU5F1B is clinically relevant in different cohorts.



**Figure 1.** Amplification of POU5F1B gene loci in various cohorts of prostate cancer. Red bar, amplifications. Green bar, mutation. Blue bar, deletion. The data were obtained from cBioportal TCGA public databases.

As shown in **Figure 1**, POU5F1B gene is frequently amplified in various cohorts of prostate cancer. In the Trenton/Cornell/Broad cohort (Beltran et al., 2016), POU5F1B is amplified in about 44% of castration resistant prostate cancer specimens. Similar frequency amplification of POU5F1B was found in another cohort of metastatic prostate cancer (FHCRC) (Kumar et al., 2016). In other cohorts, the amplifications of POU5F1B are in the range between none to up to 15%, dependent upon the stages of specimens. The data suggest that POU5F1B is frequently amplified in metastatic, castration resistance prostate cancer including neuroendocrine prostate cancer.

#### 1.2 POU5F1B expression in prostatic tissue

As cancer stem cell marker, OCT4 expression has been observed in many cancers, including breast cancer(Ezeh et al., 2005), bladder cancer(Atlasi et al., 2007), lung

cancer(Karoubi et al., 2009) and prostate cancer(Monsef et al., 2009; Sotomayor et al., 2009; Su et al., 2004). However, a recent conclusive study suggests that POU5F1B, not OCT4-A or OCT4-B, is expressed in prostate cancer cell lines and prostatic tissue (Kastler et al., 2010).

To access the clinical relevance of POU5F1B in prostate carcinogenesis, we conducted *in silico* analysis of expression profiles in a prostate cancer progression dataset (GDS2545). The dataset were obtained from 171 samples including normal, adjacent normal, primary tumors, and metastatic tumors (From left to right, **Figure 2A**). A general trend of increased POU5F1B expression was noted. Further detailed analysis of the probe intensity in the four types of tissues revealed a significant increase in POU5F1B in primary tumors and a marked increase in metastatic tumors, when compare to normal prostate or adjacent normal tissues (**Figure 2B**). It should be noted that in this dataset no POU5F1 (OCT4) expression was found. The data suggest that POU5F1B, not POU5F1 (OCT4), is responsible for prostate cancer progression.

#### 1.3. POU5F1B expression in prostate cell line and prostate carcinoma tissue

So far, six pseudogenes for OCT4 have been identified. The similarity between them and OCT4 are very high, three of them have >97% (Suo et al., 2005). The highly homologous between OCT4 and its pseudogenes can cause false positive artifacts of OCT4 expression by RT-PCR(Liedtke et al., 2008). By using OCT4 and POU5F1B specific RT-PCR, Kalster *et al.* showed it is POU5F1B, but not OCT4 is expressed in prostatic carcinoma and surrounding prostatic tissue(Kastler et al., 2010).

We can use OCT4 antibody to detect POU5F1B in prostate cell lines. First, we investigate the POU5F1B protein level in prostate tumor cell lines. Immunoblot showed POU5F1B was present in DU145, PC3, and LNCaP-T cells, a highly tumorigenic sublines of LNCaP cells. Embryonic teratoma cell, NCCIT, was used as positive control to determine the target protein band. Interestingly, POU5F1B was not detected in RWPE-1 cells, HPV-immortalized normal prostate epithelial cells (**Figure 3 A**).

Further, we examined POU5F1B expression in prostate tumor tissue by immunohistochemistry (IHC) using a validated monoclonal antibody Cell Marque MRQ-10). As shown in **Figure 3 B**, nuclear localized Oct3/4 positivity was present in the positive control (Cell Marque; CXS121). Among 44 prostate tumor tissues examined, nine had positive staining for POU5F1B. There was only one tumor section positive for POU5F1B staining out of seven prostate cancer patient specimens with the Gleason score less than three (14%), and three from 21 malignant specimens with Gleason scores from five to seven (14%). The other five tissues positive for 4 POU5F1B were from 16 prostate adenocarcinomas with Gleason scores greater than eight (31%), suggesting an increased incidence of POU5F1B positivity in high-grade prostate adenocarcinomas. In addition, the positive staining for POU5F1B in tumor specimen was mainly localized in the cell nucleus.



(B)



# Figure 2.

#### tissue.

- (A) GEO prome of recently in measure prostate cancer (HG-U95A). Dataset type: expression profiling by array, count, 171 samples.
- (B) POU5F1B expression profiles during prostate cancer progression (GDS2545/39626\_s\_at/POU5F1B/Homo sapiens). Note the significant increase in POU5F1B expression in prostate tumors, especially in metastatic tumors, when compared to adjacent normal tissue or normal prostate tissue.

(A)







#### Figure 3. POU5F1B expression in prostate cell lines and prostate carcinoma tissue.

- (A) POU5F1B expression in prostate cell lines. Western blot analysis of POUF1B expression in human embryonic teratoma cell NCCIT, immortalized prostate epithelial cell RWPE-1, and prostatic carcinoma DU145, PC3, and LNCaP cells. NCCIT was used as the positive control for OCT4 expression.
- (B) Immunohistochemistry analysis of POU5F1B in prostate carcinoma samples. Left panel is the negative control. Middle panel showed positive control (Cell MARQUE, CXS121) of POU5F1B. Right panel is a malignant prostate carcinoma tissue D16 (Gleason score= 1+2) with expression of POU5F1B. Brown color indicates positive staining. Note the nuclear localization of the staining.
- (C) Statistical analysis of POU5F1B expression in 44 prostate tumor tissues. The increased incidence of POU5F1B positive staining in higher grade prostate adenocarcinomas was noted.

## 1.4. Making pCDH-myc POU5F1B construct

To further study the function of POU5F1B gene and its translated protein product, we need to generate POU5F1B overexpression construct. The expression level of POU5F1B in cells is not high, so we use Nest-PCR to amplify this gene. First step PCR enriched the fragment including our gene of interest region. Second step, we use special primer containing 20 bps homologous to linear Vector and 20 bps specific for the gene sequence. The amplified product then was cloned into the linearized vector using cold fusion kit. A schematic overview of methodical procedure is shown in Figure 3A. In our experiment, PC3 cDNA was used as template for first PCR. The products of first PCR were shown in Figure 3B left panel.

The products of second PCR were shown in Figure 3B right panel. The band was cut from the gel and extracted, and then ligated with EcoR I and Not I linearized pCDH-myc vector using cold fusion reaction.

After we get the constructs, EcoR I and Not I enzyme digestion confirmed the inserts (Figure 3B right panel).

# DNA template GOI ORF

(B)

First round PCR product







Enzyme digestion





# Figure 4. Cloning POU5F1B protein-coding region from PC3 cDNA into pCDH-myc Vector.

- (A) Overview of methodical procedure to make construct using nest-PCR and cold fusion cloning kit. DNA contains our target sequence are used as template, first pair of PCR primers are located 111 bps upstream of POU5F1B start codon and 122 bps downstream of POU5F1B stop codon. First round PCR product, which enriched POU5F1B sequence, was used as template for second PCR. The second pair of primers contains 20 bps homologous with pCDH-myc vector and 20 bps homologous with POU5F1B sequence. This PCR product was cut from DNA gel, and then ligated with linearized pCDH-myc vector using cold fusion kit.
- (B) PCR products of cloning steps and confirmation of the insert by enzyme digested. Left panel showed first round PCR product, which enriched POU5F1B sequence. Middle panel showed second round PCR product, which contains POU5F1B coding sequence with 20 bps upstream homologous with pCDH-myc vector and 20 bps downstream homologous with pCDH-myc vector. Right panel showed confirmation of the insert by EcoR I and Not I enzyme digestion.

# 1.5 Alignment of PC3 POU5F1B ORF sequence with NCBI POU5F1B sequence (NM\_001159542.1)

The enzyme digestion confirmed constructs were sent for sequencing. When we aligned the sequence of insert with POU5F1B (NM\_001159542.1), two mismatches was noted,  $CAG^{684} \rightarrow CAA^{684}$  (Glutamine/Q $\rightarrow$ Glutamine/Q) and  $G^{712}AG \rightarrow C^{712}AG$  (Glutamic acid/E $\rightarrow$ Glutamine/Q). The first mismatch is a silent mutation, which will not cause amino acid change. The second mismatch will cause glutamic acid to glutamine change (Figure 4A). These two mismatches have been reported as SNP rs6998254 and SNP rs7002225 respectively (Figure 4B).

When compare PC3 POU5F1B amino acid sequence with NCBI POU5F1B amino acid sequence, only one amino acid changed, E<sup>238</sup> in NCBI POU5F1B but Q<sup>238</sup> in PC3 POU5F1B. When compare POU5F1B amino acid with POU5F1, we found fifteen amino acids are different, eight of them located at N domain, two located at POU specific domain, one in linker region, one in POU homeodomain and three in C domain (Figure 4C). Some amino acids change may contribute to protein structure, such as R33L, from basic, positive, polar to neutral hydrophobic; G97S, hydrophobic to polar; D108N, acid, negative to neutral; T118P, polar to hydrophobic; E135K, acidic, negative to basic, positive; T170I, polar to hydrophobic; T182K, neutral to basic, positive; Q259 polar was deleted; T351I, polar to hydrophobic (Table 1). Hans R. Schöler showed the linker between two POU domains of mouse OCT4 is exposed to the surface of the protein and it is very important for reprogramming activity of OCT4 and protein-protein interaction(Esch et al., 2013). To map the sequences or residues which are critical for the

different function between POU5F1B and OCT4 would provide more clues for better understanding why it is POU5F1B not OCT4 is expressed in prostatic carcinoma and surrounding prostatic tissue.

(A) DU5F1B	601	CGGCCCTTGCTGCAGAAGTGGGTGGAGGAAGCTGACAACAATGAAAATCTTCAGGAGATA	660
Insert	661	TGCAAAGCAGAAACCCTCATCCAAGCCCGAAAGAGAAAGCGAACCAGTATCCAGAACCGA	720
POU5F1B 661 TGCAAAGCAGAAACCCTCATCCAGGCCCGAAAGAGAAAGCG		TGCAAAGCAGAAACCCTCATCCAGGCCCGAAAGAGAAAGCGAACCAGTATCGAGAACCGA	720
Insert 721		GTGAGAGGCAACCTGGAGAATTTGTTCCTGCAGTGCCCGAAACCCACACTGCAGATCAGC	780
POU5F1B	POU5F1B 721 GTGAGAGGCAACCTGGAGAATTTGTTCCTGCAGTGCCCGAAACCCACACTGCAGA		780
Insert	Insert 781 CACATCGCCCAGCAGCTTGGGCTCGAGAAGGATGTGGTCCGAGTGTGGTTCTGTAACCG		
POU5F1B	781	CACATCGCCCAGCAGCTTGGGCTCGAGAAGGATGTGGTCCGAGTGTGGTTCTGTAACCGG	840
Insert	841	CGCCAGAAGGGCAAGCGATCAAGCAGCGACTATGCACAACGAGAGGATTTTGAGGCTGCT	900
(POU5F1B	841	CGCCAGAAGGGCAAGCGATCAAGCAGCGACTATGCACAACGAGAGGATTTTGAGGCTGCT	900
Insert /	s999 <u>8</u> 254	[Hamaisapiens] TTCTCAGGGGGACCAGTGTCCTTTCCTCCGGCCCCAGGGCCCCATTTTGGT	960
POU5F1B	TATGQAAA	GCASAACPECCATERATA/AGCECCAAACAAAASECCAFEAGTATCCGGCCCCAGGGCCCCATTTTGGT	960
	Gene:	LOC101930033 (GeneView) POU5F1B (GeneView)	
	-unctional Validated:	Consequence: intron variant,synonymous codon by 1000G,by 2hit 2allele,by cluster,by frequency	
(	Global MA	F: G=0.4793/1044	
maghl a r letsc 22. fsgkt 0	s7002225	[Homo sapiens] cpppyelcggmaycgpqv GAAAGCGAACCAGTATC[C/G]AGAACCGAGTGAGAGGCAACCTGGA vrgnlenlflgcpkptlc	vgvglvpqgg ilgvlfgkv vishiagglg
lekdv (	Chromoso	me: 8:127416578 talyssvpfpegevfppv	vsvitlgspm
hsn G	Sene: Functional	Consequence: intron variant,missense	anegeagygye
snsdga	/alidated: Global MA	E: C=0.4959/1080	eeadnnenlqei
ckaetl <del>vqark</del> (m)fpegeaft	opvsvttlg	<del>wrgmennigepkpaqqismaqqigiekawwrwwreni rqkgkrsssayaqreared</del> agspfsggpvstplapgphfgt ispmhsn5	pgygsphitalys
POU5F1 POU5F1B PC3 POU5E	1 1 11B 1	MAGHLASDFAFSPPPGGGGDGP <mark>GGP</mark> EPGWVDPRTWLSFQGPPGGPGIGPGVGPGSEVWGI MAGHLASDFAFSPPPGGGGDGPWGAEPGWVDPLTWLSFQGPPGGPGIGPGVGPGSEVWGI MAGHLASDFAFSPPPGGGGDGPWGAEPGWVDPLTWLSFOGPPGGPGIGPGVGPGSEVWGI	60 60 60
P0115 F1	61		120
POUSFIB 61 PPCPPPELCGGMAYCGPQVGVGLVPQGGLETS		PPCPPPYELCGGMAYCGPQVGVGLVPQGGLETSQPESEAGVGVESNSNGASPEPCTVPPG	120
PC3 PO05E	10 11		120
POU5F1 POU5F1B	12	1 AVKLEKEKLEQNPEESQDIKALQKELEQFAKLLKQKRITLGITQADVGLILGVLFGKVFS 21 AVKLEKEKLEQNPEKSQ <mark>DIKALQKELEQFAKLLKQKRITLGYTQADVGLILGVLFGKVFS</mark>	180
PC3 POU5E	'1B 12	1 AVKLEKEKLEQNPEKSQ <mark>DIKALQKELEQFAKLLKQKRITLGYTQADVGLILGVLFGKVFS</mark>	180
POU5F1	18	21 QTTICRFEALQLSFKNMCKLRPLLQKWVEEADNNENLQEICKAETLVQARKRKRTSIENR	240
POU5F1B 181 QKTICRFEALQLSFKNMCKLRPLLQKWVEEADNNENLQEICKAETLMQARKRKRTSI   PC3 POU5F1B 181 QKTICRFEALQLSFKNMCKLRPLLQKWVEEADNNENLQEICKAETLMQARKRKRTSI		11 OKTICKFEALQLSFKNMCKLKPLLQKWVEEADNNENLQEICKAETLMQARKKKKTSIENK 21 OKTICKFEALQLSFKNMCKLRPLLQKWVEEADNNENLQEICKAETLMQ <mark>ARKKKKTSIONK</mark>	240
POU5F1 241 VRGNLENLFLQCPKPTLQQISHIAQQLGLEKDVVRVWFCNRRQKGKRSSSDYAQREDFEA			
POU5F1B 241 VRGNLENLFLQCPKPTL*QISHIAQQLGLEKDVVRVWFCNRRQKGKRSSSDYAQREDFE		299 299	
POII5F1			360
POU5F1B 300 AGSPFSGGPVSFPPAPGPHFGTPGYGSPHFTALYSSVPFPEGEVFPPVSVITLGSPMHSN			
PC3 POU5F1B 3		0 AGSPFSGGPVSFPPAPGPHFGTPGYGSPHFTALYSSVPFPEGEVFPPVSVITLGSPMHSN	359

# Figure 5. Alignment of PC3 POU5F1B with NCBI POU5F1B (NM\_001159542.1) and NCBI POU5F1 (NM\_002701.5).

- (A) Alignment of insert sequence cloned from PC3 cDNA with NCBI POU5F1B (NM\_001159542.1) sequence. 2 mismatches were found as showed in red boxes.
- (B) Two reported SNPs in POU5F1B gene. SNP rs6998254 showed CAG<sup>684</sup> $\rightarrow$ CAA<sup>684</sup> variant allele, and SNP rs7002225 showed G<sup>712</sup>AG $\rightarrow$ C<sup>712</sup>AG variant allele.
- (C) Alignment of PC3 POU5F1B putative amino acid sequence with NCBI POU5F1B putative amino acid sequence and NCBI POU5F1 amino acid sequence. Yellow highlight indicate POU specific domain, green highlight indicate POU homeodomain, and blue highlight indicate linker between these two domains. Amino acids in red mean differences between them.

Location	OCT4	POU5F1B/PC3 POU5F1B	Domain
22	G	W	N domain
24	Р	A	N domain
33	R (Basic, Positive, Polar)	L (Neutral, Hydrophobic)	N domain
69	F	L	N domain
97	G (Hydrophobic)	S (Polar)	N domain
108	D (Acidic, Negative)	N (Neutral)	N domain
118	T (Polar)	P (Hydrophobic)	N domain
135	E (Acidic, Negative)	K (Basic,, Positive)	N domain
170	T (Polar)	I (Hydrophobic)	POUs domain
182	T (Neutral)	K (Basic, Positive)	POUs domain
227	V	М	Linker
238	E(negative, acidic)	E/Q (Neutral)	POUh domain
259	Q (Polar)	-	POUh domain
314	L	Р	C domain
344	А	v	C domain
351	T (Polar)	I (Hydrophobic)	C domain

Table 1 Differences in amino acid sequences between PC3 POU5F1B, POU5F1B, and POU5F1

We have cloned the coding region of *POU5F1B* from prostate cancer PC3 cells into a lentiviral expression vector pCDH. Sequencing revealed the presence of SNPs in the coding region of *POU5F1B* in PC3 cells when compared to the reference sequence (NM\_001159542.1) but the SNPs did not alter the deduced amino acid sequence of tumor Oct4 (POU5F1B) (**Table 2**).

		Blast with POU5F1B ORF (NM_001159542.1)		
PCDH-myc- Pou5F1B Clones	Sequenced range	Nucleotide	Amino Acid	
2	1-297, 284-1080	684(CAGCAA) 712(TCGTCC)	no change	
3	1-513 285-1080	684(CAGCAA) 712(TCGTCC)	no change	
4	1-272 285-1080	684(CAGCAA) 712(TCGTCC)	no change	

**Table 2.** Single nucleotide polymorphism in the coding region of POU5F1B cloned from prostate cancer PC-3 cells. Note the SNPs did not lead to a change in the amino acid sequence in tumor Oct4 (POU5F1B).

At the time of our study, these SNP risk associations have not been published. Complete analysis of these risk alleles with POU5F1B or Oct4 protein expression and transactivation activity has not been conducted yet, so the full extent of this association and functional consequences of these risk alleles is still not known. Nevertheless, we speculated that these SNPs contributed to the tumor functions of POU5F1B and examined the functional consequence of PC3 POU5F1B (which carries the SNPs present in all examined prostate cancer cell lines, rs6998254 and rs7002225) overexpression in prostate cancer cells. We cloned POU5F1B from cDNA of PC3 cells into a pCDH-myc lentiviral expression construct. Sequencing of our cloned insert confirmed the presence of the SNPs in PC3 POU5F1B, rs6998254 and rs7002225, and our PC3 POU5F1B protein product differs from "normal" POU5F1B at one amino acid residue. (**Fig.5A**) (Breyer et al., 2014).

#### 1.6. Validation of protein coding potential of pCDH-POU5F1B construct

To determine whether if POU5F1B have protein-encoding potential, pCDH-myc POU5F1B was transfected in to 293T cells. 48 hours later after transfection, we collected lysates from the transfected cells and did western blot analysis. As shown in **Figure 6**, showed that overexpressed protein can be detected by both myc tag mouse monoclonal antibody (abm, G019, left panel) and

OCT4 rabbit monoclonal antibody (Epitomics, 2876-1, right panel). The data confirmed the protein-encoding potential of POU5F1B.

It should be noticed that POU5F1B and POU5F1 (wild type Oct4) have 95% homology in amino acid sequence (Panagopoulos et al., 2008) and therefore, many commercial antibodies against Oct4 cannot differentiate the tumor Oct4 encoded by POU5F1B from those by POU5F1. Since POU5F1 is not expressed in prostate cancer cells (in contrast to embryonic stem cells), the Oct4 detected by immunohistochemistry or Western blot is due to the expression of its pseudogene, POU5F1B (Kastler et al.).



Myc-tag (anti-mouse, green)

Oct4 (anti-Rabbit, red)

Figure 6. Validation of the lentiviral pCDH POU5F1B expression constructs. POU5F1B was expressed as Myc tag under the promoter of EF1. Left panel, Western blot with Myc tag antibody. Right panel, Western blot with an antibody against Oct4.

#### 1.7. Overexpression of POU5F1B in prostate epithelial or tumor cells

To study the role of POU5F1B in prostate cancer progression, we packaged the lenti-virus of pCDH-myc vector and pCDH-myc POU5F1B in 293T cells, and then infected immortalized normal prostate epithelial cell, RWPE-1, and prostate cancer cell lines, LNCap, DU145, and PC3 cells. Flow cytometry was used to get the GFP positive cells. We observed the green cells under microscope (Figure 7A). Western blot using OCT4 rabbit monoclonal antibody (Epitomics, 2876-1) also confirmed the POU5F1B overexpression (Figure 7B). Immunocytochemistry of OCT4 in LNCaP and DU145 cells showed the overexpressed POU5F1B is localized in nucleus (Figure 7).



Figure 7. Establish POU5F1B overexpressed prostate cell lines.

- (A) GFP was observed in cells stably infected with pCDH myc vector or pCDH myc POU5F1B under fluorescence microscope. Stably infected cells were selected by FACS.
- (B) Western blot confirmed the overexpression in RWPE-1, LNCap, DU145, and PC3 cells infected with pCDH myc POU5F1B using OCT4 antibody.

#### 1.8. POU5F1B promotes cell migration

GEO data set suggests POU5F1B was robustly increased in metastatic prostate cancer tissue, so we want to test the effect of POU5F1B on cell migration. We did trans-well migration assay. In LNCaP cells, we found the number of cells that migrated through the pores in POU5F1B overexpression cells was  $237\pm18.37$ , which was significantly higher than that of pCDH myc vector,  $98.5\pm9.66$  (P<0.001) (**Figure 8A**). In DU145 cells, comparing 500.5±11.26 migrated

cells in POU5F1B overexpression with  $354.25\pm24.73$  migrated cells in pCDH myc vector, the increasement of migrated cell number in POU5F1B overexpressed is significant (P<0.005) (**Figure 8B**). We also checked the effect of POU5F1B on migration in PC3 cells. The data was consistent with the findings in LNCaP and DU145 cells. The number of cells that migrated through the pores in PC3-pCDH POU5F1B was  $93.75\pm11.16$ , whereas the number of cells that migrated through the pores in PC3-pCDH myc vector was  $18.50\pm5.74$  (**Figure 8C**).





## Figure 8. POU5F1B can promote cell migration.

- (A) Representative images and statistically graph of cell migration in LNCaP pCDH myc vector and LNCaP POU5F1B cells.
- (B) Representative images and statistically graph of cell migration in DU145 pCDH myc vector and DU145 POU5F1B cells.
- (C) Representative image and statistically graph of cell migration in PC3 pCDH myc vector and PC3 POU5F1B cells.

## 1.9. POU5F1B promotes colony formation in soft agar

The anchorage-independent growth (AIG) is an important step in acquisition of malignancy(Freedman and Shin, 1974). Cells with anchorage-independent growth ability have the potential to migrate through the body, colonize other tissues and grow metastatically(Gassmann and Haier, 2008). The soft agar colony formation assay is a common method to monitor anchorage-independent growth.

As showed in **Figure 9**, LNCaP POU5F1B formed  $75.5\pm7.63$  colonies in soft agar, whereas in LNCaP pCDH-myc vector, the number of colonies was significantly decreased, only  $26.75\pm7.63$  (P<0.001).



(E





(A) LNCaP pCDH vector and LNCaP POU5F1B cells were seeded on soft agar and cultured for 7 days. The stained colonies were photographed, and counted.

(B) Statistical data of clonies formed in soft agar. 4 repeats for each group. P<0.001.

# 1.10 POU5F1B causes changes the morphology of DU145 cells

We noticed that DU145 cells with POU5F1B overexpression have different cell morphology when compared with DU145-pCDH myc vector cells. DU145 pCDH-myc vector showed tightly packed and formed clustered structures, typical of epithelial cells and suggestive of strong cell-cell adhesion (**Figure 10 left panel**). DU145 cells overexpressed POU5F1B showed reduced cell-cell adherens junctions and suggestive of increased cell molitity (**Figure 10 right panel**). This observation are more significant under 200 magnification. This morphology change is consistant with previous data which showed POU5F1B can promote cell migration.



**Figure 10. Comparasion of cell morphology between DU145 pCDH myc vector and DU145 POU5F1B cells.** The tight cell-cell adherent junctions were found in DU145 pCDH myc vector cells, but were reduced in DU145 POU5F1B cells.

#### 1.11. POU5F1B induces epithelial to mesechymal transition (EMT) in DU145 cells

We observed the cells lost tight cell-cell adhesion when POU5F1B is overexpressed, which suggests the cells undergo EMT process. Down-regulation of E-Cadherin is one of the hallmarks of EMT. First, we assessed the cellular localization and expression of E-Cadherin in DU145 pCDH myc vector and DU145 POU5F1B cells. Immunocytochemistry staining showed typically E-Cadherin localization at cell-cell junction in pCDH myc vector cells, but such staining pattern was disapperaed in POU5F1B overexpressed cells (Figure 11A). Furthermore, immunoblot confirmed the down-regulation of E-Cadherin after POU5F1B overexpression (Figure 11B). The reductidon of E-Cadherin was not found in immortalized normal prostate epithelial cell line RWPE-1 cells with POU5F1B overxpression (Figure 11B). This suggest that POU5F1B decrease E-Cadherin is cell-dependent. E-Cadherin is the main component of the cell-cell adhesion junctions, loss of its expression will increase cell mitility.

To investigate other EMT-related gene expression, we did EMT-related gene microarray. As showed in **Figure 12**, the eptithelila marker, CDH1 gene, which encoding E-Cadherin decreased by almost 10 folds. The mesenchymal marker, CDH2, N-Cadherin encoding gene and CLDN1, claudin-1 encoding gene are increased. Twist, SIP-1 and Vimentin are the mesenchymal marker that are decreased in DU145 POU5F1B cells compared with DU145 pCDH cells.



Figure 11. Effect of POU5F1B on E-Cadherin cellular localization and expression.

- (A) Immunocytochemistry of E-Cadherin in DU145 pCDH and DU145 POU5F1B cells. POU5F1B causes loss of E-Cadherin localization at cell-cell junctions. DU145 pCDH myc vector and DU145 POU5F1B cells growed on coverslips were fixed, subjected to double staining with anti-E-Cadherin (red) and DAPI (blue) and examined by fluorescence microscopy.
- (B) Immunoblot of E-Cadherin in RWPE-1 pCDH and POU5F1B, DU145 pCDH and POU5F1B cells. It was noticed that POU5F1B could decrease E-Cadherin expression in DU145 cells, but not in RWPE-1 cells.



**Figure 12. POU5F1B overexpression in DU145 regulates EMT-related genes expression.** Scatter plot comparing EMT-related gene expression profiles between DU145 pCDH and DU145 POU5F1B cells. Red lines indicate fourfold increase in DU145 POU5F1B compared with DU145 pCDH cells. Green lines indicate fourfold decrease in DU145 POU5F1B compared with DU145 pCDH cells. CT value was normalized to beta-actin CT.

# 1.12. The effect of POU5F1B on tumor growth in vivo

We found POU5F1B, when overexpressed in LNCaP (FGC) cells, stimulated tumor growth. Due to prostate cancer heterogeneity, we wished to extend the findings to other prostate cancer cell lines. Surprisingly we found POU5F1B actullay suppressed the growth of tumors from PC3 or DU145 cells.

To determine whether POU5F1B promote tumor growth, we subcutaneously injected 2X10<sup>6</sup> PC3 cells with pCDH vector or POU5F1B expression, DU145 cells with pCDH vector or POU5F1B expression into nude mice. 5 mice for each group. 4 out of 5 mice formed tumor in PC3 pCDH and PC3 POU5F1B cells after injection, but tumors formed in PC3 POU5F1B cells grows much slower than PC3 pCDH cells(**Figure 13A**). In DU145 pCDH cells, 3 out of 5 mice formed tumors, and only 1 out of 5 mice formed tumor in DU145 POU5F1B cells. It is also showed that POU5F1B suppress tumor growth in DU145 cells (**Figure 13B**). POU5F1B overexpressing cells exhibit stem cell like properties. The slower tumor growth that we observed in mice is likely the result of the higher proportion of quiescient pluripotent cells, and therefore lower proportions of highly proliferative cells, that make up the POU5F1B population.



Figure 13. Suppression of tumor growth by POU5F1B in PC3 and DU145 cells.

# 1.13 Suppression of DU145 tumor growth, but not the formation of tumors, in vivo by POU5F1B

In previous reports, we found POU5F1B, when overexpressed in LNCaP-T (FGC) cells, stimulated tumor growth. Due to prostate cancer heterogeneity, we wished to extend the findings to other prostate cancer cell lines. Surprisingly we found POU5F1B actullay suppressed the growth of tumors from PC3 or DU145 cells in the last report.

We repeated the studies. As shown in **Figure 14**, POU5F1B indeed suppressed the growth of DU145 tumors, but not the formation of tumors.



Figure 14. Suppression of DU145 tumor growth by POU5F1B.

# Task 2: Determine whether tumor Oct4 can be targeted to reduce prostate tumor formation, progression, and metastasis.

We have introduced shRNA constructs into PC3MM and DU145 cells. Currently we are screening stable clones that can be used for our studies. Interestingly we found that in addition to POU5F1B, POU5F1, the putative gene for Oct4, is also expressed in the prostate cancer while we were characterizing the clones. This raises two questions: First, PCa cells may express

POU5F1, in addition to its pseudogene. Second, knockdown of POU5F1B, may have stimulated the expression of POU5F1. Since the shRNAs cannot differentiate POU5F1B from POU5F1, this complexity confound the interpretation of the data.

Currently we are using an alternative approach, the CRISPR gene editing approach, to delete POU5F1B, to determine whether its deletion can lead to reduced tumor formation, and metastasis. Additional funding are being sought to fund the alternative approach.

Task 3: Elucidate the mechanism involved for tumor Oct4 in promoting prostate carcinogenesis.

## 3.1. POU5F1B and MYC were co-amplified in same subset of prostate cancers

We analyzed the patterns of POU5F1B amplifications in association with clinical parameters such as cancer type, tumor sites, and ploidy. As shown in **Figure 15A**, POU5F1B amplifications can be found both in castration resistance prostate cancer (CRPC) adenocarnoma and CRPC neuroendocrine (NE) cancer in the Trenton/Cornell/Broad cohort (Beltran et al., 2016). The amplifications seem associated with those specimens with increased ploidy, suggesting that the gain of chromosome or chromosome segments likely lead to POU5F1B amplifications. Since MYC gene, like POU5F1B, is also located in the chromosome 8q24 region, we determined the pattern of MYC amplifications in the same cohort. As shown in the figure 2A, MYC is also frequently amplified in the similar subsets of tumor specimens from castration resistance prostate cancer.

Similar co-amplifications of POU5F1B and MYC were also found in the FHCRC cohort of metastatic prostate cancer (Kumar et al., 2016) (**Figure 15B**). The data suggest that the POU5F1B is frequently amplified with MYC gene loci in more than 40% metastatic or castration resistant prostate cancer.

# <u>(A)</u>

Cancer Type Detailed							
Ploidy							
Tumor Site							
Disease code							
POU5F1B	44%						
MYC	45%						
Genetic Alteration		Amplification					
Cancer Type Detailed		Prostate Cancer	Pros	state Neuroendocrine Carcino	na		
Ploidy		1.6 3.9					
Tumor Site		Pelvic mass Retroperitoneal	Bone mass	Lymph node Prostat	e Liver Adre	al L	Lung Epidural Skull base Soft tissue Bladder
Disease code		CRPC-NE	CRPC-Ad	eno			
<u>(B)</u>							
Cancer Type De	tai	led					
POU5F1B		4	44%				
МҮС		2	41%				
Genetic Alteration				Amplification	Deep Deleti	on	Missense Mutation (putative passenger)
Cancer Type Detai	led			Mixed	ate Adenocar	cinom	na

**Figure 15.** Co-amplifications of POU5F1B and MYC in castration resistant prostate cancer (CRPC) or metastatic prostate cancer.

# **3.2 POU5F1B expression in prostate carcinoma tissue is associated with androgen receptor** (AR).

We detected Oct4 protein expression in prostate cancer cells as well as in tumor tissue specimens. With the availability of RNAseq data from the Trenton/Cornell/Broad cohort (Beltran et al., 2016), we first checked whether amplifications of POU5F1B can lead to increased POU5F1B expression. As shown in **Figure 16A**, amplifications of POU5F1B gene loci did not necessarily lead to its increased expression, as observed in metastatic prostate cancer. The data suggest that other factors are required for increased POU5F1B expression in metastatic prostate cancer.



Figure 16. POU5F1B expression in prostate carcinoma tissue (A) and its association with AR (B).

Next we determined whether POU5F1B is associated with androgen receptor (AR) since it plays an important role in castration resistance and metastatic progression of prostate cancer. As shown in Figure 16B, there is correlation between these two in terms of the expression at RNA levels, with Pearson and Spearman coefficients as 0.30 and 0.32, respectively. The functional significance of the correlation needs further studies.

#### 3.3. POU5F1B and stemness

To investigate whether POU5F1B overrxpression can induce cancer stem cell-related genes expression, we did cancer stem cell microarray. 84 cancer stem cell related genes are investigated. The functional grouping of these genes were shown in **Table 3**. We observed a very prominent overexpression of cancer stem cell related genes after POU5F1B expression. In DU145 cells, nearly half of all tested genes were overexpressed by at least 2 folds in POU5F1B cells. In PC3 cells, 2 fold overexpression was observed in a quarter of tested genes. Most notably, we found 14 genes that are significantly overexpressed in both DU145 and PC3 POU5F1B cells, including essential pluripotency regulators NANOG, SOX2, and BMI; cell adhesion and migration molecules PECAM1, THY1, ITGA4; and oncogenes MYCN, cKIT, WNT1 (**Figure 17**).

#### Table 2. Functional grouping of cancer stem cell microarray genes

#### Table 3

Functional group	Genes
Cancer Stem Cell Markers	ABCB5, ALCAM, ALDH1A1, ATXN1, BMI1, CD24, CD34, CD38, CD44, ENG, ETFA, FLOT2, GATA3, ITGA2, ITGA4, ITGA6, ITGB1, KIT, MS4A1, MUC1, PECAM1, PROM1, PTPRC, THY1
Proliferation	EGF, ERBB2, KITLG, LIN28B, NOS2
Self-Renewal	BMP7, DNMT1, FGFR2
Pluripotency	KLF4, LIN28A, MYC, NANOG, POU5F1, SOX2
Asymmetric Division	FOXP1, HDAC1, MYCN, SIRT1, WNT1.
Migration & Metastasis	AXL, ID1, IL8, KLF17, PLAT, PLAUR, SNAi1, TWIST1, TWIST2, ZEB1, ZEB2.
Loss of Stemness	ALDH1A1, CD34, DACH1, FOXA2, PECAM1, PTCH1.
Signal Transduction Pathways	
Hippo Signaling	LATS1, MERTK, SAV1, TAZ, WWC1, YAP1
Hedgehog Signaling	PTCH1, SMO.
Notch Signaling	DLL1, DLL4, JAG1, MAML1, NOTCH1, NOTCH2
WNT Signaling	DKK1, EPCAM, FZD7, WNT1
PI3K/AKT/mTOR signaling	ABCG2, GSK3B
STAT/NFkB Signaling	IKBKB, JAK2, NFKB1
Therapeutic Targets	ABCG2, ATM, AXL, CHEK1, DDR1, DKK1, EPCAM, FZD7, GSK3B, ID1, IKBKB, JAK2, KLF17, NFKB1, PTCH1, SMO, STAT3, TGFBR1, WEE1



(A)

Normalized CT value of PC3 POU5F1B

Figure 17. Scatter plot of cancer stem cell genes expression profile between cells with pCDH vector and POU5F1B expression. Red lines indicate fourfold increase in POU5F1B compared with pCDH cells. Green lines indicate fourfold decrease in POU5F1B compared with pCDH cells. CT value was normalized to house-keeping gene CT.

- (A) Cancer stem cell genes expression profile in DU145 pCDH and DU145 POU5F1B.
- (B) Cancer stem cell genes expression profile in PC3 pCDH and PC3 POU5F1B.

#### 3.4. POU5F1B association with ATP-binding cassette efflux transporters

The data above suggest that POU5F1B induces many stemness gene signatures in DU145 and PC-3 cells. The changes suggest that POU5F1B may have reprogrammed DU145 and PC-3 stem-like phenotypes: The ability to form tumors, but not necessarily to stimulate tumor growth.

One of characteristics for cancer stem cells is the resistance toward therapeutics. The drug resistance is partially mediated by the slow cycling cells and/or ATP-binding cassette (ABC) efflux transporters. We next studied whether POU5F1B expression is related to ABC transporters. As shown in **Figure 18**, POU5F1B is associated with ABCC1 and ABCC4. ABCC4 is found upregulated in prostate cancer.



Figure 18. Association of POU5F1B with ABC efflux transporters ABCC1 (A) and ABCC4 (B).

# **KEY RESEARCH ACCOMPLISHMENT and REPORTABLE OUTCOMES**

#### **Presentations and abstracts:**

Hongmei Jiang, Man-Tzu Wang and Daotai Nie. The Role of POU5F1B in Prostate Cancer. AACR 2013 Annual Meeting, Washington, DC, 2013.

Hongmei Jiang, Man-Tzu Wang, and Daotai Nie. The Role of POU5F1B in Prostate Cancer. Simmons Cancer Institute 2013 Research Symposium, Springfield, IL, October 2013.

Hongmei Jiang, Man-Tzu Wang, Jiuhui Wang, Yande Guo, Yuanqin Zhang, and Daotai Nie, POU5F1B, an OCT4 Retrogene, Suppresses Uncontrolled Tumor Growth. Keystone Meeting on Molecular and Cellular Basis of Growth and Regeneration (A3), Breckenridge, Colorado USA, January 2016.

#### **Abstracts published:**

Hongmei Jiang, Man-Tzu Wang and Daotai Nie. The Role of POU5F1B in Prostate Cancer. Proc. Amer. Assoc. Cancer Res. 52 Late breaking: LB-281, 2013.

#### **Review article published:**

Man-Tzu Wang, Hongmei Jiang, Debasish Boral and Daotai Nie. Cancer Stem Cells in Resistance to Cytotoxic Drugs: Implications in Chemotherapy. B. Bonavida (ed.), Molecular Mechanisms of Tumor Cell Resistance to Chemotherapy, Resistance to Targeted Anti-Cancer Therapeutics 1, DOI: 10.1007/978-1-4614-7070-0\_8, Springer Science+Business Media New York 2013.

#### **Research articles published:**

The manuscript requires further revisions.

# **Conclusions and significance (So what?):**

Our studies found that:

- 1. POU5F1B, the pseudogene of POU5F1 localized in prostate cancer susceptibility loci 8q24, is frequently amplified in castration resistant metastatic prostate cancer.
- 2. POU5F1B expression is associated with AR expression level expressed in prostate cancer.
- 3. The expression of POU5F1B was found increased in prostate tumors when compared to adjacent normal tissues or normal prostate tissues and it was markedly increased in metastatic prostate carcinoma, compared to primary tumors or normal prostate tissues.
- 4. POU5F1B was cloned from prostate cancer cells. Sequencing found two SNPs when compared to the reference sequence, but the SNPs did not cause amino acid sequence changes.
- 5. Prostate cancer cells with increased POU5F1B expression had increased migratory phenotype and decreased E-cadherin expression at protein or mRNA level.
- 6. POU5F1B effect on tumor growth can be context dependent. In some cells (LNCaP), POU5F1B promoted tumor growth but in other cells (PC-3 and DU145), POU5F1B suppressed tumor growth, but not the formation of tumors. The divergence may be due to their differential dependence on AR signaling.
- 7. POU5F1B expression led to increased "stemness" signature and associated expression of ABC transporters ABCC1 and ABCC4.

Our studies suggest complex roles of POU5F1B in prostate carcinogenesis. More studies are needed to determine when and how POU5F1B can be targeted to reduce prostate cancer metastasis.

## **APPENDICES**

N/A

## SUPPORTING DATA

Embedded in the reporting body

## REFERENCES

Atlasi, Y., Mowla, S. J., Ziaee, S. A., and Bahrami, A. R. (2007). OCT-4, an embryonic stem cell marker, is highly expressed in bladder cancer. International journal of cancer Journal international du cancer *120*, 1598-1602.

Beltran, H., Prandi, D., Mosquera, J. M., Benelli, M., Puca, L., Cyrta, J., Marotz, C., Giannopoulou, E., Chakravarthi, B. V., Varambally, S., *et al.* (2016). Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nature medicine *22*, 298-305.

Breyer, J. P., Dorset, D. C., Clark, T. A., Bradley, K. M., Wahlfors, T. A., McReynolds, K. M., Maynard, W. H., Chang, S. S., Cookson, M. S., Smith, J. A., *et al.* (2014). An expressed retrogene of the master embryonic stem cell gene POU5F1 is associated with prostate cancer susceptibility. American journal of human genetics *94*, 395-404.

Esch, D., Vahokoski, J., Groves, M. R., Pogenberg, V., Cojocaru, V., Vom Bruch, H., Han, D., Drexler, H. C., Arauzo-Bravo, M. J., Ng, C. K., *et al.* (2013). A unique Oct4 interface is crucial for reprogramming to pluripotency. Nature cell biology *15*, 295-301.

Ezeh, U. I., Turek, P. J., Reijo, R. A., and Clark, A. T. (2005). Human embryonic stem cell genes OCT4, NANOG, STELLAR, and GDF3 are expressed in both seminoma and breast carcinoma. Cancer *104*, 2255-2265.

Freedman, V. H., and Shin, S. I. (1974). Cellular tumorigenicity in nude mice: correlation with cell growth in semi-solid medium. Cell *3*, 355-359.

Gassmann, P., and Haier, J. (2008). The tumor cell-host organ interface in the early onset of metastatic organ colonisation. Clinical & experimental metastasis 25, 171-181.

Hayashi, H., Arao, T., Togashi, Y., Kato, H., Fujita, Y., De Velasco, M. A., Kimura, H., Matsumoto, K., Tanaka, K., Okamoto, I., *et al.* (2013). The OCT4 pseudogene POU5F1B is amplified and promotes an aggressive phenotype in gastric cancer. Oncogene.

Karoubi, G., Gugger, M., Schmid, R., and Dutly, A. (2009). OCT4 expression in human non-small cell lung cancer: implications for therapeutic intervention. Interactive cardiovascular and thoracic surgery *8*, 393-397.

Kastler, S., Honold, L., Luedeke, M., Kuefer, R., Moller, P., Hoegel, J., Vogel, W., Maier, C., and Assum, G. POU5F1P1, a putative cancer susceptibility gene, is overexpressed in prostatic carcinoma. The Prostate *70*, 666-674.

Kastler, S., Honold, L., Luedeke, M., Kuefer, R., Moller, P., Hoegel, J., Vogel, W., Maier, C., and Assum, G. (2010). POU5F1P1, a putative cancer susceptibility gene, is overexpressed in prostatic carcinoma. The Prostate *70*, 666-674.

Kumar, A., Coleman, I., Morrissey, C., Zhang, X., True, L. D., Gulati, R., Etzioni, R., Bolouri, H., Montgomery, B., White, T., *et al.* (2016). Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer. Nature medicine *22*, 369-378.

Liedtke, S., Stephan, M., and Kogler, G. (2008). Oct4 expression revisited: potential pitfalls for data misinterpretation in stem cell research. Biological chemistry *389*, 845-850.

Monsef, N., Soller, M., Isaksson, M., Abrahamsson, P. A., and Panagopoulos, I. (2009). The expression of pluripotency marker Oct 3/4 in prostate cancer and benign prostate hyperplasia. The Prostate *69*, 909-916.

Panagopoulos, I., Moller, E., Collin, A., and Mertens, F. (2008). The POU5F1P1 pseudogene encodes a putative protein similar to POU5F1 isoform 1. Oncology reports *20*, 1029-1033.

Sotomayor, P., Godoy, A., Smith, G. J., and Huss, W. J. (2009). Oct4A is expressed by a subpopulation of prostate neuroendocrine cells. The Prostate *69*, 401-410.

Su, A. I., Wiltshire, T., Batalov, S., Lapp, H., Ching, K. A., Block, D., Zhang, J., Soden, R., Hayakawa, M., Kreiman, G., *et al.* (2004). A gene atlas of the mouse and human protein-encoding transcriptomes. Proceedings of the National Academy of Sciences of the United States of America *101*, 6062-6067.

Suo, G., Han, J., Wang, X., Zhang, J., Zhao, Y., Zhao, Y., and Dai, J. (2005). Oct4 pseudogenes are transcribed in cancers. Biochemical and biophysical research communications *337*, 1047-1051.